Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology company Volpara has increased its revenue by 197 per cent to sit at roughly $6.4 million dollars
  • Highlights during this period include the successful purchase of Seattle-based MRS Systems for $18 million
  • The company now remains on track to meet its mid-range forecast for annual recurring revenue of $16.1 million
  • Volpara is down just over five per cent with shares trading for $1.99 apiece

Medical technology company Volpara has increased its half-year revenue by 197 per cent to sit at NZ$6.8 million (AUD$6.4 million).

Highlights during the half-year include the successful acquisition of Seattle-based MRS Systems for US$14.6 million (AUD$18 million) and the raise of AUD$55 million in capital during the first quarter.

Following the successful capital raise and acquisition, the Board made a deliberate decision to continue to invest in the business by increasing the sales, marketing and customer capability.

This bought additional resources into engineering for research and development, as well as strengthening the executive team with new roles in operations, people and customer success.

The combined team now has the resources and product suite to go on and capture market share which has been successful to date.

The integration of MRS Systems into Volpara has provided the company with a full suite of breast-screening products and an enhanced database that can now be optimised moving forward.

It will enable Volpara to increase the number of women in the key U.S. market who have a product used during breast cancer treatment.

“MRS Systems has been successfully integrated into Volpara and we are already seeing our hard work translate into increased customer numbers,” Volpara CEO Dr Ralph Highnam said.

“We can now optimise the benefits that MRS has brought to Volpara, which includes a bolstered database. We come to the table with a stronger offering to help our patients beat cancer,” he added.

The company also saw a 215 per cent increase in gross profit to NZ$6.1 million (AUD$5.7 million) and subscription revenue up 148 per cent to NZ$5.2 million (AUD$4.8 million).

“This past half-year has positioned us well financially for our next stage of growth. We have funds from a successful capital raise, a more solid cash position, stronger revenue streams and a full suite of breast-screening products,” Dr Ralph said.

However, loss after tax was up 55 per cent on the previous corresponding period, which includes one-off acquisition costs of NZ$620,000 (AUD$583,000) and other material non-cash expenses.

Volpara now remains on track to meet its mid-range forecast for ARR (annual recurring revenue) for the year of NZ$17.1 million (AUS$16.1 million).

Volpara is down just over five per cent today with shares trading for $1.99 at 1:28 pm AEDT.

VHT by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.